McKesson (MCK)
(Delayed Data from NYSE)
$549.31 USD
+24.03 (4.57%)
Updated Nov 6, 2024 04:00 PM ET
Pre-Market: $591.00 +41.69 (7.59%) 9:16 AM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$549.31 USD
+24.03 (4.57%)
Updated Nov 6, 2024 04:00 PM ET
Pre-Market: $591.00 +41.69 (7.59%) 9:16 AM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
Is SPDR Russell 1000 Momentum Focus ETF (ONEO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEO
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Evolut PRO+ launch in Europe and Evolut PRO launch in China are expected to have contributed to the company's fiscal Q3 top line.
Neogen's (NEOG) Synergize Disinfectant Now Widely Available
by Zacks Equity Research
Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.
Should SPDR Russell 1000 Momentum Focus ETF (ONEO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEO
NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Cardinal Health's (CAH) Velocare to Enhance at-Home Care
by Zacks Equity Research
Cardinal Health's (CAH) latest launch is expected to significantly expand its at-Home Solutions supply chain and logistics services, thereby improving patient care.
3 Reasons to Retain Abbott (ABT) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business.
PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health
by Zacks Equity Research
PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.
Phibro (PAHC) Q1 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Phibro's (PAHC) growing uptake of MFAs, dairy products and vaccines buoys optimism.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Patterson Companies' (PDCO) New Buyout to Expand Product Suite
by Zacks Equity Research
Patterson Companies' (PDCO) latest buyout is expected to significantly expand its Animal Health's product offerings.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.
Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment
by Zacks Equity Research
Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Beat the Market Like Zacks: JPMorgan, Berkshire Hathaway, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Improving margins buoy optimism.
Patterson Companies (PDCO) Inks Deal to Expand Product Suite
by Zacks Equity Research
Patterson Companies' (PDCO) latest buyout is expected to significantly expand its value-add platform.
October CPI Data Raises Hope for a Soft Landing: 5 Top Picks
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths with solid growth potential. These are: HUM, MPC, CAT, MCK and ORLY.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Zacks Industry Outlook Highlights Becton Dickinson, McKesson and AmerisourceBergen
by Zacks Equity Research
Becton Dickinson, McKesson and AmerisourceBergen have been highlighted in this Industry Outlook article.
3 Dental Supplies Stocks to Watch Amid Industry Headwinds
by Indrajit Bandyopadhyay
Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, MCK and ABC.
Zacks.com featured highlights H&R Block, ParkerHannifin, Archer-Daniels-Midland, Insperity and McKesson
by Zacks Equity Research
H&R Block, ParkerHannifin, Archer-Daniels-Midland, Insperity and McKesson have been highlighted in this Screen of The Week article.
3 Reasons Growth Investors Will Love McKesson (MCK)
by Zacks Equity Research
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.